Klertis (Sunitinib Cyclamate)

• Klertis (sunitinib cyclamate) is used in oncology to inhibit tumor growth driven by specific tyrosine‑kinase pathways.
• Renal cell carcinoma: inhibits VEGFR and PDGFR signaling, reducing tumor angiogenesis and cell proliferation, which can improve progression‑free and overall survival in patients with advanced disease.
• Gastrointestinal stromal tumor: blocks KIT and PDGFRA tyrosine‑kinase activity, leading to tumor shrinkage, disease stabilization, and prolonged progression‑free survival in patients with unresectable or metastatic GIST.

• Sunitinib cyclamate exerts its antineoplastic effect by competitively inhibiting multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR‑1, ‑2, ‑3), platelet‑derived growth factor receptors (PDGFR‑α, ‑β), stem‑cell factor receptor KIT, and FLT3. By blocking these pathways, the drug suppresses endothelial cell proliferation, tumor angiogenesis, and direct tumor cell growth, resulting in reduced tumor vascularization and proliferation.

Sunitinib cyclamate may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Fatigue: persistent tiredness affecting daily activities.
• Diarrhea: loose stools that may require hydration.
• Hand‑foot syndrome: redness, swelling, or pain on palms and soles.
• Hypertension: elevated blood pressure that may need monitoring or medication.

Serious or Rare Side Effects

• Cardiac dysfunction: reduced left‑ventricular ejection fraction or heart failure.
• Thromboembolic events: deep‑vein thrombosis or pulmonary embolism.
• Severe hepatic toxicity: marked elevation of liver enzymes or hepatitis.

Before initiating Klertis, several safety considerations should be reviewed to minimize risk.

• Baseline cardiovascular assessment: evaluate blood pressure and cardiac function prior to therapy.
• Liver function monitoring: perform regular tests of ALT, AST, and bilirubin during treatment.
• Hematologic surveillance: check complete blood counts periodically for neutropenia or thrombocytopenia.
• Drug interaction review: assess concomitant medications that affect CYP3A4 metabolism.
• Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Sunitinib cyclamate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce plasma concentrations.
• Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase exposure and risk of toxicity.

Moderate Interactions (Monitor Closely)

• Anticoagulants (warfarin, direct oral anticoagulants): heightened bleeding risk; monitor coagulation parameters.
• Antihypertensive agents: blood pressure may rise; adjust antihypertensive therapy as needed.
• St. John’s wort: may lower sunitinib levels; advise patients to avoid herbal supplements.